Search results
Eric B. Lev General Partner. Wellesley. Eric, who joined Ampersand in 2013, has 18 years of middle market healthcare investment experience. Eric’s current and past board seats include ALPCO, Biologos, Biosynth, CutisPharma, Genoptix, iuvo Biosciences, LakePharma, Leinco Technologies, Nexelis, Nexcelom Biosciences, P95 and Resolian (formerly Alliance Pharma).
Mar 19, 2024 · Eric Lev adds, "The investment in Biologos aligns well with Ampersand's strategy of supporting growth-oriented life science organizations with a history of product innovation and customer ...
Nov 17, 2021 · Eric Lev, General Partner at Ampersand and incoming Board member of Leinco, added, “Leinco is a tremendous fit with Ampersand’s investment strategy of supporting growth-oriented life science and healthcare organizations with established leadership positions in specialty segments of the market.
View Eric Lev’s profile on LinkedIn, a professional community of 1 billion members. Experience: Aegon Asset Management · Education: USC Marshall School of Business · Location: Los Angeles ...
- 500+
- Multifamily Asset Management
- Aegon Asset Management
- Los Angeles
Eric Lev, General Partner at Ampersand noted, “P95 is another great fit in Ampersand’s strategy of supporting pharma services companies with leadership positions based on differentiated ...
From 2005 to 2013, Mr. Lev was a principal at Water Street Healthcare Partners, and served before then as Group Manager, Strategy & Business Development at Beckman Coulter from 2004 to 2005. Mr. Lev also previously served as an associate on the healthcare/life sciences team at One Equity Partners and began his career as an analyst in the ...
Eric B Lev is Partner at Ampersand Venture Mgmt Corp. See Eric B Lev's compensation, career history, education, & memberships.
